The burden of multiple myeloma: assessment on occurrence, outcomes and cost using a retrospective longitudinal study based on administrative claims database


Objective: Multiple myeloma (MM) is a malignancy of plasma cells that results in an overproduction of light and heavy chain monoclonal immunoglobulins. Multiple myeloma imposes a significant economic and humanistic burden on patients and society. The present study is aimed at assessing the burden of multiple myeloma in both epidemiologic and economic terms.

Methods: A retrospective, naturalistic longitudinal study on the occurrence, outcome and cost of multiple myeloma using an administrative database, was performed. We selected residents of a North-eastern Region of Italy, who had their first hospital admission for multiple myeloma during the period 2001-2005. This group was followed up until 31-12-2006, death or transfers to other regional health services. Direct medical costs were quantified within the perspective of the Regional Health Service.

Results: During the period 2001-2005, out of a population if 1.2 million inhabitants, we observed 517 incidents of patients diagnosed with MM (52% female). During the period of observation, 364 (70.4%) subjects died. Total health care costs per patient over the maximum of follow-up were estimated to be 76,630 Euro for subjects younger than 70 years old and 22,892 Euro in the older group.

Conclusions: Multiple myeloma imposes a significant epidemiological and economic burden on the healthcare system.


Administrative database; cost; incidence; multiple myeloma

Full Text:






  • There are currently no refbacks.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it (Read more).